BG107370A - Novel interferon for treatment of multiple sclerosis - Google Patents

Novel interferon for treatment of multiple sclerosis

Info

Publication number
BG107370A
BG107370A BG107370A BG10737002A BG107370A BG 107370 A BG107370 A BG 107370A BG 107370 A BG107370 A BG 107370A BG 10737002 A BG10737002 A BG 10737002A BG 107370 A BG107370 A BG 107370A
Authority
BG
Bulgaria
Prior art keywords
multiple sclerosis
treatment
beta2
inf
interferon
Prior art date
Application number
BG107370A
Other languages
Bulgarian (bg)
English (en)
Inventor
Edward CROZE
Daryl Faulds
Charis WAGNER
Original Assignee
Schering Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Aktiengesellschaft filed Critical Schering Aktiengesellschaft
Publication of BG107370A publication Critical patent/BG107370A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BG107370A 2000-06-16 2002-12-11 Novel interferon for treatment of multiple sclerosis BG107370A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (fr) 2000-06-16 2001-06-18 Nouvel interferon destine au traitement de la sclerose en plaques

Publications (1)

Publication Number Publication Date
BG107370A true BG107370A (en) 2003-11-28

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
BG107370A BG107370A (en) 2000-06-16 2002-12-11 Novel interferon for treatment of multiple sclerosis

Country Status (22)

Country Link
US (1) US20020025304A1 (fr)
EP (1) EP1289541A2 (fr)
JP (1) JP2004505021A (fr)
KR (1) KR20030009529A (fr)
CN (1) CN1436086A (fr)
AU (1) AU2001267099A1 (fr)
BG (1) BG107370A (fr)
BR (1) BR0111852A (fr)
CA (1) CA2413077A1 (fr)
CZ (1) CZ20024094A3 (fr)
EE (1) EE200200693A (fr)
HU (1) HUP0300787A2 (fr)
IL (1) IL152996A0 (fr)
LT (1) LT2002123A (fr)
MX (1) MXPA02012308A (fr)
NO (1) NO20025964L (fr)
NZ (1) NZ522849A (fr)
PL (1) PL359562A1 (fr)
RU (1) RU2003100517A (fr)
SI (1) SI21080A (fr)
SK (1) SK17612002A3 (fr)
WO (1) WO2001095929A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006506097A (ja) * 2002-11-18 2006-02-23 マキシジェン, インコーポレイテッド インターフェロン−αのポリペプチドおよび結合体
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
EP1712992A1 (fr) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Mise-à-jour d'instructions de données
US8895700B2 (en) 2010-02-18 2014-11-25 Janssen Biotech, Inc. Monkey homolog of human interferon omega
ES2877568T3 (es) 2016-02-05 2021-11-17 Orionis Biosciences Nv Agentes de unión de Clec9A
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
US10906985B2 (en) 2017-02-06 2021-02-02 Orionis Biosciences, Inc. Targeted engineered interferon and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
SI9520059A (en) * 1994-05-10 1997-08-31 Immulogic Pharma Corp Compositions and treatment for multiple sclerosis.
US6299869B1 (en) * 1997-12-08 2001-10-09 Genentech, Inc. Human interferon-epsilon: a type I interferon
EA200001252A1 (ru) * 1998-05-29 2001-06-25 Байоджен, Инк. КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
JP2002526078A (ja) * 1998-09-18 2002-08-20 ザイモジェネティクス,インコーポレイティド インターフェロン−イプシロン
US20030175897A1 (en) * 2000-04-14 2003-09-18 Thayer Edward C. Human interferon, Zinf2

Also Published As

Publication number Publication date
CN1436086A (zh) 2003-08-13
SI21080A (sl) 2003-06-30
MXPA02012308A (es) 2003-04-25
RU2003100517A (ru) 2004-06-27
LT2002123A (en) 2003-06-25
IL152996A0 (en) 2003-06-24
US20020025304A1 (en) 2002-02-28
NO20025964L (no) 2003-02-14
CZ20024094A3 (cs) 2003-05-14
EE200200693A (et) 2004-06-15
SK17612002A3 (sk) 2003-08-05
KR20030009529A (ko) 2003-01-29
EP1289541A2 (fr) 2003-03-12
NO20025964D0 (no) 2002-12-12
CA2413077A1 (fr) 2001-12-20
JP2004505021A (ja) 2004-02-19
HUP0300787A2 (hu) 2003-07-28
NZ522849A (en) 2004-05-28
PL359562A1 (en) 2004-08-23
WO2001095929A3 (fr) 2002-10-10
WO2001095929A2 (fr) 2001-12-20
AU2001267099A1 (en) 2001-12-24
BR0111852A (pt) 2003-05-20

Similar Documents

Publication Publication Date Title
EP1033998A4 (fr) Procedes de suppression des modifications liees aux beta-amyloides dans la maladie d'alzheimer
NZ248377A (en) Use of interleukin-1 beta protease and interleukin-1 beta protease inhibitors
DE69914463D1 (en) Therapeutische chemokine rezeptor antagonisten
ATE406176T1 (de) Il-1-inhibitor in kombinationstherapie zur behandlung il-1-vermittelter krankheiten
PT735818E (pt) Proteinas inflamatorias de macrofagos pim-3 pim-4 e pim-1y
EP0457195A3 (en) Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same
MX9703643A (es) Metodos para tratamiento de esclerosis multiple usando analogos de peptidos de proteina basica de mielina humana.
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
EP1429800A4 (fr) Vaccin et methode de traitement de maladies du motoneurone
BG107370A (en) Novel interferon for treatment of multiple sclerosis
DE69625682T2 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
GB0127983D0 (en) Treatment of micro-organism infection
PT1259536E (pt) Métodos de preparação de péptidos
DE50010519D1 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
WO2004043373A3 (fr) Precurseur n-acetylgalactosamine-4-sulfatase, methodes de traitement au moyen dudit enzyme et procedes de production et de purification dudit enzyme
IL145722A0 (en) Pharmaceutical composition comprising growth hormone and interferon
RU2004104335A (ru) Биологически активные пептиды
WO2004074312A3 (fr) Peptides de tryptophylline et utilisations correspondantes
UA66749C2 (en) Actin-resistant variants of human dnase i, isolated nucleic acid, a method for treatment of patients suffering from pulmonary diseases
KR950704358A (ko) 카텝신 l 특이적 저해 폴리펩티드
WO2000026362A3 (fr) Proteines de la famille de la stomatine et leur utilisation comme proteines cibles pour le traitement de la douleur
AU7435298A (en) Compositions for enhancing immunosuppressants' pharmaceutical acti vities